New Drug to Treat Major Depression

Glaxosmith kline is conducting or will have conducted clinical trial studies of compound GW856553 to treat major depression.The study is in phase 2 clinical trials which means it should take another 5 years pending approval, before it hits the pharmacy shelves.Its truly promising to see active research going into treating depression.It is a disease often underdiagnosed and payed little attention too.Its about time to move on from fluoxetine(prozac) which has a host of side effects....
Check out the reference below if you are interested, they are currently recruiting research candidates to take part in the clinical trials.........

Stay well all....

Reference
http://clinicaltrials.gov/ct2/show/NCT00976560?term=NEW+DRUGS&rank=20

FDA approves new ADHD treatment

Acording to the FDA website the drug INTUNIV(guanfacin) has resently been approved for use in the treatment of ADHD in children and adolescents aged 6 to 17.According to the drugs official website the clinical trials for this drug where shown to relieve symtoms of ADHD.The drug is expected to be in pharmacies accross the USA by november 2009.

This is encouraging news, ADHD can be very desruptive to peoples lives

References
http://www.intuniv.com

New radiotherapy treatment for lung cancer

The lancet outlines some new treatment advances for those with non-operable small cell lung cancer (SCLC).They is a by SUNY department of radiation on the use of different radiation based treatment regimes to treat SCLC. In the article it mentions four major radiation based treatment types for SCLC. These include:

1)External beam radiotherapy
2)Three-dimensional conformal radiotherapy
3)Stereotactic body radiation therapy (SBRT)
4)Intraoperative brachytherapy
5)Radiofrequency ablation

For details of the the research check reference and as always ask docter or suitable medical professional regarding these new treatments...takecare and stay well

Reference
The Lancet Oncology, Volume 10, Issue 9, Pages 885 - 894, September 2009

Treatment advances for medically inoperable non-small-cell lung cancer: emphasis on prospective trials
Original TextJohn W Powell MD a, Elisabeth Dexter MD b, Ernest M Scalzetti MD c, Prof Jeffrey A Bogart MD a